Kiora Pharmaceuticals Inc KPRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.48
- Day Range
- $2.47–2.57
- 52-Week Range
- $1.76–3.29
- Bid/Ask
- $2.45 / $2.58
- Shares Outstanding
- 4.43M
- Market Cap
- $11.30M
- Volume/Avg
- 111,823 / 39,316
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 13
- Website
- https://www.kiorapharma.com
Valuation
|
Metric
|
KPRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.71 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
KPRX
Financial Strength
|
Metric
|
KPRX
|
|---|---|
Quick Ratio | 6.19 |
Current Ratio | 6.68 |
Interest Coverage | — |
Quick Ratio
KPRX
Profitability
|
Metric
|
KPRX
|
|---|---|
Return on Assets (Normalized) | −26.37% |
Return on Equity (Normalized) | −37.91% |
Return on Invested Capital (Normalized) | −40.52% |
Return on Assets
KPRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|TnTSRF | LOCK|fQwJ | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|><wl<bm | LOCK|QD!lg | $70B | |||
| argenx SE ADR
ARGX
| LOCK|@G%>jY | LOCK|>< | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>mj?g&m | LOCK|%B@V | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|QHwZMg< | LOCK|sh^ | $37B | |||
| Moderna Inc
MRNA
| LOCK|!C$#X&N | LOCK|?b! | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$F>Khs$ | LOCK|?b@& | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|M@D>@V | LOCK|$Yz | $23B | |||
| Incyte Corp
INCY
| LOCK|#mg?G#j | LOCK|h! | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|>Dvw<$ | LOCK|s!! | $16B |
United States